The Effect of Topical Bromfenac on Intraretinal and Subretinal Fluid in Neovascular Age-Related Macular Degeneration

PURPOSE: To report the effect of topical bromfenac, a non-steroidal anti-inflammatory drug (NSAID), in a case of neovascular age-related macular degeneration (AMD). METHODS: An 85-year-old woman presented with a complaint of visual acuity reduction in the right eye. Comprehensive ophthalmological ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdolrahimzadeh, Solmaz, Fameli, Valeria, Tizio, Federico Di, Staso, Federico Di, Fenicia, Vito, Scuderi, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337015/
https://www.ncbi.nlm.nih.gov/pubmed/32671307
http://dx.doi.org/10.4103/JOCO.JOCO_105_20
Descripción
Sumario:PURPOSE: To report the effect of topical bromfenac, a non-steroidal anti-inflammatory drug (NSAID), in a case of neovascular age-related macular degeneration (AMD). METHODS: An 85-year-old woman presented with a complaint of visual acuity reduction in the right eye. Comprehensive ophthalmological examination and retinal imaging were performed. RESULTS: Best corrected visual acuity was 2/100. Fundus examination showed reticular pseudodrusen and a small hemorrhage in the fovea. Fluorescein angiography showed an active neovascular membrane. Spectral-domain optical coherence tomography (SD-OCT) confirmed diagnosis and revealed subretinal and intraretinal fluid. The patient refused recommended intravitreal anti-vascular endothelial growth factor treatment and received topical bromfenac 0.09% twice daily. Follow-up with SD-OCT showed subretinal followed by intraretinal fluid reduction at 16 weeks after treatment. CONCLUSION: Short-term reduction of subretinal and intraretinal fluid was observed with topical bromfenac monotherapy in neovascular AMD.

Ejemplares similares